Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors

Psychopharmacology

Volumn 120, Issue 1, 1995, Pages 67-74

  Corbett, R ^a   Camacho, F ^a   Woods, A T ^a   Kerman, L L ^a   Fishkin, R J ^a   Brooks, K ^a   Dunn, R W ^a  

^a SANOFI   (France)

Author keywords

Antipsychotic agents; Dopamine; Non competitive NMDA antagonists; Schizophrenia; Social withdrawal

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ATROPINE; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; DEXAMPHETAMINE; DIZOCILPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PRAZOSIN; RACLOPRIDE; RADIOLIGAND; RISPERIDONE; RITANSERIN; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; CLIMBING; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL ISOLATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINE; ANIMAL; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; N-METHYLASPARTATE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 0029030343     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02246146     Document Type: Article

References (37)

1. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
2. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
3. Molecular biology of the dopamine receptors
4. Effects of atypical antipsychotic agents on social behavior in rodents
5. Mesolimbic involvement with behavioral effects indicating antipsychotic activity
6. Climbing behavior induced by apomorphine in mice: a potent model for the detection of neuroleptic activity
7. The two syndrome concept and neuroendocrinology of schizophrenia
8. A glutamatergic hypothesis of schizophrenia
9. Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice
10. Effects of neuroleptics on phencycliding (PCP)-induced locomotor stimulation in mice
11. A social interaction model of anxiety sensitive to acutely administered benzodiazepines
12. Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for dopaminergic role in some PCP-induced behaviors
13. Effect of olanzapine on rat brain binding, acetylcholine levels and monoamine turnover
14. The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytrptamine1C and 5-hydroxytryptamine2 receptors
15. Clozapine for the treatment-resistant schizophrenic
16. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus
17. Is it possible to model psychotic states in animals?
18. Recent advances in the phencyclidine model of schizophrenia
19. Phencyclidine: behavioral and biochemical evidence supporting a role for dopamine
20. Do negative symptoms respond to pharmacological treatment?
21. Clozapine for the treatment-resistant schizophrenic
22. The phencyclidine (PCP) analog N-[1[2-benzo (B) thiophenyl) cyclohexyl] piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801
23. Presynaptic dopaminergic modulation of cortical input to the striatum
24. A simplified method of evaluating dose effect experiments
25. Classification of typical and atypical antipsychotic drug on the basis of dopamine D1, D2 and serotonin2 pKi values
26. Treatment of the neuroleptic nonresponsive schizophrenic patients
27. Therapeutic effect and safety of increasing doses of risperidone (R64744) in psychotic patients
28. The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent
29. Dopamine receptor sequences therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4
30. In the rat nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other
31. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
32. Glycine potentiates N-methyl- d-aspartate induced [3H] TCP binding to rat cortical membranes
33. MK-801-induced stereotypy and its antagonism by neuroleptic drugs
34. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
35. Modulation of MK-801 response by dopaminergic agents in mice
36. Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes
37. Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens